Literature DB >> 22952334

Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial.

Katja Sockel, Martin Bornhaeuser, Eva Mischak-Weissinger, Rudolf Trenschel, Martin Wermke, Christian Unzicker, Guido Kobbe, Jürgen Finke, Ulrich Germing, Brigitte Mohr, Jochen Greiner, Dietrich Beelen, Christian Thiede, Gerhard Ehninger, Uwe Platzbecker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22952334      PMCID： PMC3436225          DOI： 10.3324/haematol.2012.067629

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Eva M Weissinger; Eric Schiffer; Bernd Hertenstein; James L Ferrara; Ernst Holler; Michael Stadler; Hans-Jochem Kolb; Axel Zander; Petra Zürbig; Markus Kellmann; Arnold Ganser
Journal:  Blood       Date:  2007-03-05       Impact factor: 22.113

2.  Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus.

Authors:  U Platzbecker; B Mohr; M von Bonin; M Binder; J Schetelig; G Ehninger; M Bornhäuser
Journal:  Leukemia       Date:  2007-06-21       Impact factor: 11.528

3.  Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.

Authors:  M C Minnema; M S van der Veer; T Aarts; M Emmelot; T Mutis; H M Lokhorst
Journal:  Leukemia       Date:  2008-09-11       Impact factor: 11.528

4.  Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Authors:  A Ferrant; M Labopin; F Frassoni; H G Prentice; J Y Cahn; D Blaise; J Reiffers; G Visani; M A Sanz; M A Boogaerts; B Löwenberg; N C Gorin
Journal:  Blood       Date:  1997-10-15       Impact factor: 22.113

5.  Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.

Authors:  Hanneke M van der Straaten; Anja van Biezen; Ronald Brand; Anton V M B Schattenberg; Roel M Egeler; Renée M Barge; Jan J Cornelissen; Harry C Schouten; Gert J Ossenkoppele; Leo F Verdonck
Journal:  Haematologica       Date:  2005-10       Impact factor: 9.941

6.  Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.

Authors:  David H Chang; Nancy Liu; Virginia Klimek; Hani Hassoun; Amitabha Mazumder; Stephen D Nimer; Sundar Jagannath; Madhav V Dhodapkar
Journal:  Blood       Date:  2006-03-28       Impact factor: 22.113

7.  Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.

Authors:  Evelien Kneppers; Bronno van der Holt; Marie-Jose Kersten; Sonja Zweegman; Ellen Meijer; Gerwin Huls; Jan J Cornelissen; Jeroen J Janssen; Cynthia Huisman; Petra B Cornelisse; Cheryl P Bruijnen; Maarten Emmelot; Pieter Sonneveld; Henk M Lokhorst; Tuna Mutis; Monique C Minnema
Journal:  Blood       Date:  2011-06-20       Impact factor: 22.113

8.  Thalidomide for the treatment of chronic graft-versus-host disease.

Authors:  G B Vogelsang; E R Farmer; A D Hess; V Altamonte; W E Beschorner; D A Jabs; R L Corio; L S Levin; O M Colvin; J R Wingard
Journal:  N Engl J Med       Date:  1992-04-16       Impact factor: 91.245

9.  Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.

Authors:  U Platzbecker; M Wermke; J Radke; U Oelschlaegel; F Seltmann; A Kiani; I-M Klut; H Knoth; C Röllig; J Schetelig; B Mohr; X Graehlert; G Ehninger; M Bornhäuser; C Thiede
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

10.  Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation.

Authors:  J M McDaniel; J X Zou; W Fulp; D-T Chen; A F List; P K Epling-Burnette
Journal:  Leukemia       Date:  2011-12-23       Impact factor: 12.883
View more
  25 in total

Review 1.  Reduced-intensity conditioned allogeneic SCT in adults with AML.

Authors:  R Reshef; D L Porter
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

Review 2.  The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60years.

Authors:  Sarah A Wall; Steven Devine; Sumithira Vasu
Journal:  Blood Rev       Date:  2017-07-15       Impact factor: 8.250

3.  Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant.

Authors:  Rohtesh S Mehta; Antonio Di Stasi; Chitra Hosing; Nina Shah; Katayoun Rezvani; Amin Alousi; Susan O'Brien; William Wierda; Michael Keating; Elizabeth J Shpall
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-12-27

Review 4.  Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.

Authors:  Armin Rashidi; Roland B Walter; Martin S Tallman; Frederick R Appelbaum; John F DiPersio
Journal:  Blood       Date:  2016-06-27       Impact factor: 22.113

Review 5.  Life after transplant: are we becoming high maintenance in AML?

Authors:  A M Brunner; A T Fathi; Y B Chen
Journal:  Bone Marrow Transplant       Date:  2016-06-20       Impact factor: 5.483

Review 6.  Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.

Authors:  Robert J Soiffer; Yi-Bin Chen
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 7.  Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.

Authors:  Robert J Soiffer; Yi-Bin Chen
Journal:  Blood Adv       Date:  2017-11-28

8.  Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.

Authors:  Charles Craddock; Myriam Labopin; Marie Robin; Juergen Finke; Patrice Chevallier; Ibrahim Yakoub-Agha; Jean Henri Bourhis; Henrik Sengelov; Didier Blaise; Thomas Luft; Michael Hallek; Nicolaus Kröger; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2016-04-14       Impact factor: 9.941

Review 9.  Optimal therapy for adult patients with acute myeloid leukemia in first complete remission.

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2014-06

Review 10.  When to transplant MDS, and what to do when transplant fails.

Authors:  Katja Sockel; Uwe Platzbecker
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.